Guidance cut to single-digit; monsoon and margin collapse sour outlook

Bayer India revenue booked last year; Q1 'very nominal.' International setup ongoing; no Q1 revenue.

OPM 11.9%, margin compression. Price hikes in June unsustainable; reversed by May-July. Revenue-volume both down 12.6-12.7%.

Three products; two launched by call date, third by August end. Contribution to Q1 nil. Total new product ITI 11.56% (low).

40% June rainfall deficit; 12.6% revenue decline; herbicide segment down ~25%. PAT collapsed 34.6% YoY.

Analyst noted 'steep cut in PPT.' Management now guides single-digit growth. Guidance explicitly downgraded.

Prior (FY26 call): 'Low double-digit growth.' Current: 'Small single-digit growth' (mid-call). Monsoon 40% June deficit forced revision.

Prior guidance emphasized 'full impact of acquired Bayer products.' Q1 actual: India revenue 'very nominal', zero in international. Ramp expected Q2+ only.

Prior highlighted re-introduction as driver. Q1 actual: only two of three products launched; new product contribution 11.56% (low). Full contribution expected Q2 onward.

Q1 EBITDA near breakeven (₹-1 Cr). Full-year guidance: ₹-4 to -5 Cr EBITDA. Plant not yet accretive to profit; remains capex-heavy cash drag.

Management claimed 'price pass-ons' would maintain margins. June hikes unsustainable; reversed by May-July. Margin compression to 11.9% OPM.

Management declined to share: 'As of now, we are not sharing the number...will address separately.'

Monsoon movement and impact forced revised view; 'absolutely appropriate to project clear picture to investors.' Still hopeful Q2/Q3 growth.

Plant designed for significant automation, global safety standards, labor efficiency. No specific ROI timeline given ('not right time to comment on asset turns').

Revenue ₹26 Cr (vs ₹16 Cr prior), EBITDA <₹1 Cr (vs -₹3 Cr prior). Full-year guidance ₹65 Cr revenue; EBITDA loss ₹4-5 Cr.

India business started last year; Q1 'very nominal figure.' Major turnover (grapes/Iprovalicarb) in September Q2.

Yes, 'small single-digit growth' for FY27. Biologicals offset crop protection decline.

Two already introduced; third by August end. Two more nutrition biologicals in FY27. All regulatory approvals received.

Q4 FY28 commissioning. CGST benefits from Maharashtra govt received.

FY27-28: ~₹100 Cr Nagpur CAPEX. Dahej details TBD. No benefit quantification given.

Regulation design favors organized. Smaller/unorganized will have 'relatively lesser room to operate.' 'I hope so' we capture share.

No. 'Breakeven appears to be difficult...around negative ₹4-5 Cr.' They are 'trying hard, but I think it is difficult.'

Almost equal. Value down 12.56%, volume down 12.7%. Price hike June unsustainable; reversed by May-July. No net price growth.

Depends on irrigation. Irrigated farms (60%) will spend more; rain-fed will opt for low-cost options. Vegetable prices up, supporting horticulture demand.

Monsoon-dependent. Based on June 40% rain deficit improving to 15% by July end. Growth contingent on Q2-Q3 recovery and biostimulant ramp.

Cost inflation not fully passed through (price hikes June unsustainable). Margin compression evident in Q1 (11.9% OPM).

Land acquired, project in planning phase. Automated formulation facility with CGST benefits. Dahej capex details TBD.

June rainfall 40% below normal; delayed sowing in Rajasthan, Gujarat, MP, Maharashtra. Herbicides (42% of mix) down ~25%. Risk: Further monsoon deficit in July-Sept would deepen downturn.

Raw material and logistics costs elevated. June price hikes (offset geopolitical tensions in West Asia) unsustainable; reversed by May-July. OPM 11.9% compressed. PAT down 34.6% despite cost controls (expenses flat). Weak demand limited pass-through.

Dahej chemical synthesis facility Q1 revenue ₹26 Cr, EBITDA near zero (₹-1 Cr). Full-year guidance: ₹-4 to -5 Cr EBITDA loss. Plant acquired via Bayer deal; not yet profitable. Risk: Multi-year drag on group profitability.

Bayer India business generated minimal Q1 revenue ('very nominal'). International setup (Brazil, Europe distributors) ongoing; no revenue booked. Major ramp (grapes/Iprovalicarb) expected Q2+ (September). Risk: Timing slip or market adoption slower than expected.

Biostimulants/biologicals were banned. Two of three products just relaunched by call date; third by Aug end. New product ITI only 11.56% of Q1 revenue. Analyst estimated ₹130 Cr opportunity, but MD frames as 'fallback option' and 'reworking category.' Risk: Market adoption slow or margins compressed vs. expectations.

FY26 call promised 'low double-digit FY27 revenue growth.' Q1 delivered -12.6% decline. Guidance cut to 'single-digit growth' (disclosed in Q&A, not proactively). Multiple analysts pressed on cut severity. Risk: Repeat miss could further erode credibility.

GST notice received on certain molecules (biostimulant classification). CFO confident will win (categorized as fertilizer, 5% rate vs. higher rate). Unresolved; resolution timeline TBD.